HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Twice Retired Herbalife CEO Johnson Returns To Helm For $1 Salary Plus Stock Incentives

Executive Summary

Michael Johnson previously was CEO from 2003 to 2017 and from 2019 to early 2020, as well as chairman from 2007 to early 2020. Direct seller granted him an equity-based long-term incentive plan in stock appreciation rights and restricted stock units.

You may also be interested in...



US Q4 Consumer Health Earnings Preview: Supply Chain Disruption Returns, Opill Launch Waits

Attacks on shipping since November in the Red Sea lead shipping lines to re-route vessels south of Africa, spiking shipping costs. Perrigo began 2024 saying it expects sales of Opill oral contraceptive to start early in the first quarter, but now expects to start late in the quarter.

Herbalife Sees ‘Saturation’ In Price Increases, Potential Marketing To Weight Loss Drug Patients

Wellness, nutrition and weight loss direct seller announces it’s launching vegan product line in US and is considering a nutrition and lifestyle program its distributors could offer to consumers prescribed drugs for diabetes management and weight loss. 

Following 6.3% Q1 Sales Slump, Herbalife Expects To Ride North America To Turnaround

Direct seller declines to provide guidance due to dynamic macroeconomic environment but expects a return to growth by end of year led by North America.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153264

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel